Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Konstantin V. Menshikov"'
Autor:
Alexander V. Sultanbaev, Shamil I. Musin, Konstantin V. Menshikov, Nadezda I. Sultanbaeva, Irina A. Tuzankina, Danila O. Lipatov, Irina A. Menshikova, Mikhail V. Sultanbaev, Dmitry A. Kudlay, Andrey P. Prodeus
Publikováno v:
Современная онкология, Vol 26, Iss 2, Pp 132-138 (2024)
Background. In oncology, of particular interest is the study of the T-cell receptor excision circles (TREC) and the κ-deletion B-cell receptor excision circles (KREC), which are extrachromosomal DNA structures. In many malignancies, the effectivenes
Externí odkaz:
https://doaj.org/article/5ed0020daa5b4dd1849ab3aab2568c61
Autor:
Igor V. Samoylenko, Yulia M. Kolontareva, Ekaterina V. Kogay, Natalia V. Zhukova, Igor A. Utyashev, Mikhail E. Ivannikov, Konstantin V. Menshikov, Maxim V. Zinkevich, Kristina V. Orlova, Yulia V. Vakhabova, Mikhail V. Volkonsky, Natalia A. Beliaeva, Ivan I. Butkov, Elena V. Karabina, Tatyana L. Moskovkina, Kseniya A. Moshkova, Olga V. Plishkina, Vitaliy D. Sychev, Oxana S. Cheplukhova, Vera V. Chernova, Alexandr N. Yurchenkov, Ksenia G. Babina, Nikita A. Savelov, Lev V. Demidov
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundAmong several treatment options for BRAF-mutant metastatic melanoma, a combination of BRAF inhibitor, MEK inhibitor, and anti-PDL1 antibody seems to be a new emergent approach recently registered in the Russian Federation. It is still not c
Externí odkaz:
https://doaj.org/article/91fe8f49496a4d33a30456c3a9114984
Autor:
Maria I. Volkova, Alexey S. Kalpinskiy, Olesya A. Goncharova, Konstantin V. Menshikov, Elena V. Karabina, Aleksand S. Dergunov, Natalya I. Polshina, Elena N. Alexandrova, Andrey A. Lebedinets, Alexey К. Panov, Alexander V. Sultanbaev, Evgeny A. Usynin, Mikhail V. Volkonskiy, Viktorya V. Mikhalyuk, Ruslan A. Zukov, Yulia V. Anzhiganova, Magomed A. Gusniev, Elena N. Igumnova, Svetlana V. Kuzmicheva, Ilya A. Pokataev, Anna S. Olshanskaya, Natalia I. Pervakova, Elvira L. Parsadanova, Tatyana A. Sannikova, Alexandr A. Bystrov, Daria M. Dubovichenko, Mukhitova R. Miliausha, Viacheslav A. Chubenko, Konstantin A. Shkret, Mariya N. Gorshenina, Mavzhuda К. Davlatova, Alina E. Kosareva, Olga A. Lutoshkina, Oxana A. Maslova, Maria V. Makhnutina, Anna V. Mishina, Makhabbat Zh. Murzalina, Oksana A. Podyacheva, Sergey A. Kalinin, Ovsep A. Mailyan, Alfiya R. Safarova, Ksenia O. Semenova, Mariya A. Strokova, Ekaterina Yu. Urashkina, Olesya S. Shmygina
Publikováno v:
Современная онкология, Vol 26, Iss 1, Pp 39-47 (2024)
Aim To evaluate the safety and toxicity of lenvatinib with pembrolizumab in unselected patients with advanced renal cell carcinoma (RCC). Materials and methods. The Russian phase IV observational study included 151 patients with advanced RCC who r
Externí odkaz:
https://doaj.org/article/b8f04fb084054d4fa93d3b87907a155b
Autor:
Alexander V. Sultanbaev, Irina V. Kolyadina, Konstantin V. Menshikov, Shamil I. Musin, Ainur F. Nasretdinov, Nadezda I. Sultanbaeva, Radmir R. Rakhimov, Danila O. Lipatov, Irina A. Menshikova, Adel A. Izmailov, Elena E. Lipatova
Publikováno v:
Современная онкология, Vol 26, Iss 1, Pp 65-72 (2024)
Background. The combination of alpelisib with fulvestrant is the optimal targeted endocrine therapy for patients with hormone-positive (HR+) HER2-negative (HER2-) metastatic breast cancer (mBC) with mutations in the PIK3CA gene. This regimen has been
Externí odkaz:
https://doaj.org/article/e3c845b4890840dc9606d4f6fb39fad8
Autor:
Alexander V. Sultanbaev, Irina V. Kolyadina, Irina R. Gilyazova, Ainur F. Nasretdinov, Shamil I. Musin, Nadezda I. Sultanbaeva, Konstantin V. Menshikov
Publikováno v:
Современная онкология, Vol 26, Iss 1, Pp 48-55 (2024)
Carriers of germinal mutations are at high risk of developing malignant neoplasms, characterized by an early age of manifestation, an aggressive course, and a high risk of recurrence. The wide introduction of medical genetic testing in the target pop
Externí odkaz:
https://doaj.org/article/e66b61080f3f4d0e823f5fd21c6b01f5
Autor:
Maria I. Volkova, Alexey S. Kalpinskiy, Konstantin V. Menshikov, Lilia V. Gorbuleva, Alexander V. Sultanbaev, Olga I. Evsyukova, Varazdat R. Meltonian, Sergey V. Mishugin, Mikhail R. Maturov, Anna S. Olshanskaya, Dmitrii Iu. Shemetov, Tatyana A. Sannikova, Mariia V. Makhnutina, Marina A. Filipieva, Elena A. Gaijsina, Elena G. Ovchinnikova, Ovsep A. Mailian, Boris Ya. Alekseev, Vsevolod B. Matveev
Publikováno v:
Современная онкология, Vol 25, Iss 2, Pp 221-228 (2023)
Aim. To assess the safety and to analyze an influence of cabozantinib monotherapy toxicity on treatment efficacy in unselected Russian patients with metastatic renal cell carcinoma (mRCC). Materials and methods. Medical data of 92 patients with ve
Externí odkaz:
https://doaj.org/article/661c9556c8fd45debb7fe8c15b3a720b
Autor:
Ainur F. Nasretdinov, Konstantin V. Menshikov, Alexander V. Sultanbaev, Shamil I. Musin, Nadezda I. Sultanbaeva, Irina A. Men'shikova
Publikováno v:
Современная онкология, Vol 24, Iss 3, Pp 340-344 (2022)
Knowledge of the molecular characteristics of the progression of non-small cell lung tumors currently provides the patient with the best treatment options. One of the most well-known and studied genetic abnormalities is a mutation in the EGFR gene, w
Externí odkaz:
https://doaj.org/article/ebd429d188994256bcbd1e16341b2425
Autor:
Tatyana N. Sokolova, Tatyana I. Solov'eva, Svetlana N. Aleksakhina, Grigorii A. Janus, Alla Goryainova, Mark I. Gluzman, Rashida V. Orlova, Anastasiya I. Stukan, Ruslan A. Zukov, Alena V. Zyuzyukina, Yulia N. Murunova, Aleksandr V. Sultanbaev, Elena N. Vorobeva, Leonid M. Mikhaevich, Victoria N. Pyliv, Anna N. Lysenko, Zarema K. Khachmamuk, Andrey E. Kozlov, Sergey Y. Bakharev, Shahen G. Parsyan, Elena I. Rossokha, Leri D. Osidze, Irina S. Shumskaya, Anna V. Agaeva, Tatiana A. Kasmynina, Veronika V. Klimenko, Kamila T. Akhmetgareeva, Almira A. Vakhitova, Madina D. Chakhkieva, Vadim N. Dmitriev, Yana I. Bakshun, Alexey E. Vasilyev, Dunya D. Gasimly, Nadezhda A. Kravchenko, Dmitriy A. Maksimov, Alfia I. Nesterova, Ineza O. Sharvashidze, Christina H. Gadzaova, Galina G. Rakhmankulova, Zaur M. Khamgokov, Irina K. Amirkhanova, Ludmila V. Bembeeva, Vladimir I. Vladimirov, Oleg L. Petrenko, Natalia G. Ruskova, Ekaterina L. Serikova, Ksenia S. Subbotina, Svetlana A. Tkachenko, Victor L. Chang, Sanal P. Erdniev, Victoria S. Barbara, Anna V. Vasilevskaya, Yulia V. Mikheeva, Nataliya O. Popova, Ekaterina P. Startseva, Anastasia V. Fateeva, Denis Y. Yukalchuk, Anna A. Grechkina, Khedi S. Musaeva, Svetlana V. Odintsova, Alena S. Stel'makh, Petimat I. Khabibulaeva, Alina G. Khlobystina, Kseniya A. Shvaiko, Elena A. Basova, Irina A. Bogomolova, Marina B. Bolieva, Viktor E. Goldberg, Marianna V. Kibisheva, Konstantin V. Menshikov, Dmitrii V. Ryazanov, Mariya L. Stepanova, Yana A. Udalova, Aleksandr V. Shkradyuk, Yana S. Chapko, Anna A. Shchukina, Idris M. Khabriev, Dmitrii V. Kirtbaya, Alexey M. Degtyarev, Aleksandr A. Epkhiev, Yana A. Tyugina, Mirza A. Murachuev, Aleksandr V. Togo, Aglaya G. Ievleva, Evgenii N. Imyanitov
Publikováno v:
Современная онкология, Vol 24, Iss 1, Pp 12-23 (2022)
Background. By 2020, breast cancer (BC) has become the most frequent malignancy in the world. The most common type of BC is HR+/HER2-negative cancer,2540% of which harbors PIK3CA mutations that affect the catalytic subunit of the PI3K protein. PIK3CA
Externí odkaz:
https://doaj.org/article/ac2dc051d6cd4d1686520ce6a60f66af
Autor:
Tatiana N. Sokolova, Svetlana N. Aleksakhina, Grigoriy A. Yanus, Aleksandr V. Sultanbaev, Konstantin V. Menshikov, Anna N. Lysenko, Ruslan A. Zukov, Alena V. Zyuzyukina, Yulia N. Murunova, Elena I. Rossokha, Sergey Y. Bakharev, Elena A. Basova, Tatiana A. Kasmynina, Irina S. Shumskaya, Yana I. Bakshun, Khedi S. Musaeva, Alfia I. Khasanova, Vadim N. Dmitriev, Marina B. Bolieva, Christina H. Gadzaova, Oleg L. Petrenko, Dmitriy A. Maksimov, Vladimir I. Vladimirov, Viktor E. Goldberg, Nataliya O. Popova, Marianna V. Kibisheva, Zaur M. Khamgokov, Alexey E. Vasilyev, Aglaya G. Iyevleva, Evgeny N. Imyanitov
Publikováno v:
Современная онкология, Vol 23, Iss 1, Pp 61-67 (2021)
Relevance. PIK3CA belongs to the top three most frequently mutated genes in breast cancer (BC), especially in estrogen receptor (ER) positive, HER2 negative BC subtype. With an approval of selective PI3K-alpha inhibitor, alpelisib, this alteration ha
Externí odkaz:
https://doaj.org/article/49ac17b627194a6ea7e6222ff26d5a94
Publikováno v:
Современная онкология, Vol 23, Iss 1, Pp 156-161 (2021)
Hepatocellular carcinoma (HCC) or liver cancer is the most common primary malignant tumor of the liver, which is characterized on the first place by a poor prognosis. HCC was diagnosed in 92 patients (62.6%) in 2019 and the period from January to Apr
Externí odkaz:
https://doaj.org/article/c0cfd0526a68496b9746ee7f2af922a5